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Abstract.
The holy grail of tumor modeling is to formulate theoretical and computational
tools that can be utilized in the clinic to predict neoplastic progression and propose
individualized optimal treatment strategies to control cancer growth. In order
to develop such a predictive model, one must account for the numerous complex
mechanisms involved in tumor growth. Here we review resarch work that we have done
toward the development of an“Ising model” of cancer. The Ising model is an idealized
statistical-mechanical model of ferromagnetism that is based on simple local-interaction
rules, but nonetheless leads to basic insights and features of real magnets, such as phase
transitions with a critical point. The review begins with a description of a minimalist
four-dimensional (three dimensions in space and one in time) cellular automaton (CA)
model of cancer in which healthy cells transition between states (proliferative, hypoxic,
and necrotic) according to simple local rules and their present states, which can viewed
as a stripped-down Ising model of cancer. This model is applied to model the growth
of glioblastoma multiforme, the most malignant of brain cancers. This is followed by a
discussion of the extension of the model to study the effect on the tumor dynamics and
geometry of a mutated subpopulation. A discussion of how tumor growth is affected
by chemotherapeutic treatment, including induced resistance, is then described. How
angiogenesis as well as the heterogeneous and confined environment in which a tumor
grows is incorporated in the CA model is discussed. The characterization of the level
of organization of the invasive network around a solid tumor using spanning trees
is subsequently described. Then, we describe open problems and future promising
avenues for future research, including the need to develop better molecular-based
models that incorporate the true heterogeneous environment over wide range of length
and time scales (via imaging data), cell motility, oncogenes, tumor suppressor genes
and cell-cell communication. A discussion about the need to bring to bear the powerful
machinery of the theory of heterogeneous media to better understand the behavior of
cancer in its microenvironment is presented. Finally, we propose the possibility of
using optimization techniques, which have been used profitably to understand physical
phenomena, in order to devise therapeutic (chemotherapy/radiation ) strategies and
to understand tumorigenesis itself.
PACS numbers: 87.17.Aa, 87.19.xj
Keywords: tumor growth, glioblastoma multiforme, cellular automaton, heterogeneous
media, optimization
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1. Introduction
Cancer is not a single disease, but rather a highly complex and heterogeneous set of
diseases. Dynamic changes in the genome, epigenome, transcriptome and proteome that
result in the gain of function of oncoproteins or the loss of function of tumor suppressor
proteins underlie the development of all cancers. While some of the mechanisms that
govern the transformation of normal cells into malignant ones are rather well understood
[1], many mechanisms are either not fully understood or are unknown at the moment.
Even if all of the mechanisms could be identified and comprehended, it is not clear
progress in understanding cancer could be made without knowledge of how these
different mechanisms couple to one another. It has been observed that many complex
interactions occur between tumor cells, and between a cancer and the host environment.
Multidirectional feedback loops occur between tumor cells and the stroma, immune
cells, extracellular matrix and vasculature [2, 3, 4, 5], which are not well understood
synergistically. Clearly, our current state of knowledge is insufficient to deduce clinical
outcome, not to mention how to control cancer progression in the most malignant forms
of cancer.
This suggests that a more quantitative approach to understanding different cancers
is necessary in order to control it and increase the lifetime of patients with these deadly
diseases. Theoretical/computational modeling of cancer when appropriately linked with
experiments and data offers a promising avenue for such an understanding. Such
modeling of tumor growth using a variety of different approaches has been a very active
area of research for the last two decades or so [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24] but clearly is in its infancy. A diverse number of mechanisms
have been explored via such models, and a multitude of computational/mathematical
techniques have been employed; see Ref. [25] for a review. These models have the
common aim of predicting certain features of tumor growth in the hope of finding
new ways to control neoplastic progression. Given a model which yields reproducible
and accurate predictions, the effects of different genetic, epigenetic and environmental
changes, as well as the impact of therapeutically targeting different aspects of the
tumor, can be probed. However, these models must be linked to data from experimental
assays in a comprehensive and systematic fashion in order to develop of a quantitative
understanding of cancer.
The holy grail of computational tumor modeling is to develop a simulation tool that
can be utilized in the clinic to predict neoplastic progression and response to treatment.
Not only must such a model incorporate the many feedback loops involved in neoplastic
progression, the model must also account for the fact that cancer progression involves
events occurring over a range of spatial and temporal scales [15]. A successful model
would enable one to broaden the conclusions drawn from existing medical data, suggest
new experiments, test new hypotheses, predict behavior in experimentally unobservable
situations, and be employed for early detection.
There is overwhelming evidence that cancer of all types are emerging, opportunistic
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systems [26]. Success in treating various cancers as a self-organizing complex dynamical
systems will require unconventional, innovative approaches and the combined effort of
an interdisciplinary team of researchers. A lofty long-term goal of such an endeavor is
not only to obtain a quantitative understanding of tumorigenesis but to limit and control
the expansion of a solid tumor mass and the infiltration of cells from such masses into
healthy tissue.
Figure 1: Picture of an Ising model.
Because a comprehensive review of the vast literature concerning biophysical cancer
modeling is beyond the scope of this article, we focus on reviewing the work that we
have done toward the development of an “Ising model” of cancer. The Ising model is an
idealized statistical-mechanical model of ferromagnetism that is based on simple local-
interaction rules (see Figure 1), but nonetheless leads to basic insights and features
of real magnets, such as phase transitions with a critical point. Toward the goal of
developing an analogous Ising model of cancer, we have formulated a four-dimensional
(4D) (three dimensions in space and one in time) cellular automaton (CA) model for
brain tumor growth dynamics and its treatment [11, 12, 13, 18, 20, 21]. Like the Ising
model for magnets, we will see later that this involves local rules for how healthy cells
transition into various types of cancer cells. Before describing our computational models
for tumor growth, we first briefly summarize several salient features of solid tumor
growth as applied to glioblastoma multiforme (GBM), the most malignant of brain
cancers.
The rest of paper is organized as follows: In Section 2, some background concerning
GBMs and solid tumors in general is presented. In Section 3, a minimalist 4D CA tumor
growth model is described in which healthy cells transition between states (proliferative,
hypoxic, and necrotic) according to simple local rules and their present states, and apply
it to GBMs. This is followed by a discussion of the extension of the model to study the
effect on the tumor dynamics and geometry of a mutated subpopulation. How tumor
growth is affected by chemotherapeutic treatment is also discussed, including induced
resistance. In Section 4, the modification of the CA model to include explicitly the effects
of vasculature evolution and angiogenesis on tumor growth are discussed. In Section
5, the effects of physical confinement and heterogeneous environment are described. In
Section 6, a simulation tool for tumor growth that merges and improves individual CA
models is presented. In Section 7, a descriptions if given of how one might characterize
the invasive network organization around a solid tumor using spanning trees. Section 8
discusses some open problems and promising avenues for future research.
2. GBM and Solid Tumor Background
Figure 2: The picture of a tumor in brain.
Glioblastoma multiforme (GBM) (see Figure 2), the most aggressive of the gliomas,
is a collection of tumors arising from the glial cells or their precursors in the central
nervous system [27].Unfortunately, despite advances made in cancer biology, the median
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survival time for a patient diagnosed with GBM is only 12-15 months, a fact that has
not changed significantly over the past several decades [28]. As suggested by its name
(i.e., “multiforme”), GBM is complex at many levels of organization [27]. It exhibits
diversity at the macroscopic level, having necrotic, hypoxic and proliferative regions.
At the mesoscopic level, tumor cell interactions, microvascular remodeling [29] and
pseudopalisading necrosis are observed [30]. Further, the discovery that tumor stem
cells may be the sole malignant cell type with the ability to proliferate, self-renew and
differentiate introduces yet another level of mesoscopic complexity to GBM [31, 32]. At
the microscopic level, GBM cells exhibit point mutations, chromosomal deletions, and
chromosomal amplifications [27].
Figure 3: The picture of a MTS.
A substantial amount of research has been conducted to model macroscopic
tumor growth either based on microscopic considerations [33, 34, 35]; or in a more
phenomenological fashion [6, 36]. One of the early attempts to model empircally the
volume V of a solid tumor versus time t is the Gompertz model, i.e.,
V = V0 exp
(
A
B
[1− exp(−Bt)]
)
, (1)
where V0 is the volume at time t = 0 and A and B are parameters; see Ref. [37] and
references therein. Qualitatively, this equation gives exponential growth at small times
which then saturates at large times (decelerating growth). In particular, this model
considers the tumor as an oversized idealized multicellular tumor spheroid (see Figure
3), which is stage of early tumor growth. We note that modeling an ideal tumor as
an oversized spheroid is especially suited for GBM, since this tumor, like a large MTS,
comprises large areas of central necrosis surrounded by a rapidly expanding shell of
viable cells (Figure 2). However, we note that real tumors always possess much more
complex morphology. More importantly, Gompertzian-growth models are very limited;
they only capture gross features of tumor growth and cannot explain their underlying
“microscopic” mechanisms.
One of the hallmarks of high-grade malignant neuroepithelial tumors, such as
glioblastoma multiforme (GBM), is the regional heterogeneity, i.e., the relatively large
number of clonal strains or subpopulations present within an individual tumor of
monoclonal origin [38, 39, 40]. Each of these strains is characterized by specific
properties, such as the rate of division or the level of susceptibility to treatment
[41]. Therefore the growth dynamics of a single tumor are determined by the
relative behaviors of each separate subpopulation. For example, the appearance of
a rapidly dividing strain can substantially bias tumor growth in that direction. Tumors
supposedly harbor cells with an increased mutation rate, which indicates that these
tumors are genetically unstable [42, 43, 44]. Genetic and epigenetic events throughout
the tumor may occur randomly or be triggered by environmental and intrinsic stresses.
The continuing existence of a subpopulation, however, depends primarily on the
subpopulation’s ability to compete with the dominant population in its immediate
vicinity.
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Clonal heterogeneity within a tumor has been shown to have very pronounced effects
on treatment efficacy [45, 46]. Treatment resistance is itself a complex phenomenon.
There is no single cause of resistance, and many biochemical aspects of resistance are
poorly understood. Chemoresistant strains can either be resistant to a single drug
or drug family (individual resistance), or they can be resistant to an array of agents
(multidrug/pleotropic resistance) [47]. Cellular mechanisms behind multidrug resistance
include increased chemical efflux and/or decreased chemical influx, such as with P-
glycoprotein-mediated (P-gp) drug resistance [48, 49].
Complicating the situation further, resistance can arise at variable times during
tumor development. Some tumors are resistant to chemotherapy from the onset. This
has been described as inherent resistance, because it exists before chemotherapeutic
drugs are ever introduced. In other cases, however, treatment initially proves successful,
and only later does the tumor prove resistant. This is an example of acquired resistance,
as it develops in response to treatment [47]. There are at least two possible mechanisms
for this type of tumor behavior. Acquired resistance may result from a small number of
resistant cells that are gradually selected for throughout the course of treatment. At the
same time, there is also evidence suggesting that chemotherapeutic agents may induce
genetic or epigenetic changes within tumor cells, leading to a resistant phenotype [50].
Other studies indicate that chemotherapy may increase cellular levels of P-gp mRNA
and protein in various forms of human cancer [51, 52]. A tumor’s response to radiation
therapy can also depend on underlying genetic factors. A cell’s inherent radio-resistance
may stem from the efficiency of DNA repair mechanisms in sublethally damaged cells
[53, 54, 55].
While the properties of GBM cells are very important in understanding growth
dynamics, just as important are the properties of the environment in which the tumor
grows. For example, GBMs grow in either the brain or spinal cord, and are therefore
confined by the shape and size of these organs [20]. Another example of the importance
of accounting for the host environment relates to the vascular structure of the brain.
Recent research evidence suggests that tumors arising in vascularized tissue such
as the brain do not originate avascularly [29], as originally thought. Instead, it is
hypothesized that glioma growth is a process involving vessel co-option, regression
and growth. Three key proteins, vascular endothelial growth factor (VEGF) and
the angiopoietins, angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), are required to
mediate these processes [29]. A picture of what likely occurs during the process of glioma
vascularization has been summarized by Gevertz and Torquato [18]. As a malignant
mass grows, the tumor cells co-opt the mature vessels of the surrounding brain that
express constant levels of bound Ang-1. Vessel co-option leads to the upregulation in
Ang-2 and this shifts the ratio of bound Ang-2 to bound Ang-1. In the absence of
VEGF, this shift destabilizes the co-opted vessels within the tumor center and marks
them for regression [56, 57]. Vessel regression in the absence of vessel growth leads to
the formation of hypoxic regions in the tumor mass. Hypoxia induces the expression
of VEGF, stimulating the growth of new blood vessels [58]. This robust angiogenic
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response eventually rescues the suffocating tumor. Glioma growth dynamics remain
intricately tied to the continuing processes of vessel regression and growth.
Tumor cell invasion is a hallmark of gliomas [59]. Individual glioma cells have been
observed to spread diffusely over long distances and can migrate into regions of the
brain essential for the survival of the patient [27]. While MRI scans can recognize mass
tumor lesions, these scans are not sensitive enough to identify malignant cells that have
spread well beyond the tumor region [60]. Typically, when a solid tumor is removed,
these invasive cells are left behind and tumor recurrence is almost inevitable [27].
Numerous models have been developed to model certain tumor behavior or
characteristics with a great deal of mathematical rigor (e.g., in the form of coupled
differential equations). However, with such approaches, the sets of equations that govern
tumor behavior often do not correspond to the characteristics of individual tumor cells.
An important goal of studying tumor development is to illustrate how their macroscopic
traits stem from their microscopic properties. In addition, most of the equations are
problem-specific, which limits their utility as general tools for tumor study. Another
potential challenge is that tumor models should be appreciated by as diverse an audience
as possible. Ideally, the mathematical complexity that allows theoreticians to analyze
subtle aspects of it should not be an obstacle for clinicians who treat GBM. A model
that accounts for complex tumor behavior with relative mathematical ease could be
valuable.
To this end, we have developed what appears to be a powerful cellular automaton
(CA) computational tool for tumor modeling. Based on a few salient set of microscopic
parameters, this CA model can realistically model the macroscopic tumor behavior,
including growth dynamics, emergence of a subpopulation as well as the effects of tumor
treatment and resistance [11, 12, 13]. This model has been extended to study the effects
of vasculature evolution on early tumor growth and to simulate tumor growth in confined
heterogeneous environments [18, 20, 21]. We have also developed mathematical models
to characterize the invasive network organization around a solid tumor [61].
3. Toward an Ising Model of Cancer Growth
In this section, we describe a four-dimensional (4D) cellular automaton (CA) model that
we have developed that describes tumor growth as a function of time, using the fewest
number of microscopic parameters [11, 12, 13]. We refer to this as a minimalist four-
dimensional (4D) model because it involves three spatial dimensions and one dimension
in time with the goal of capturing the salient features of tumor growth with a minimal
number of parameters. The algorithm takes into account that this growth starts out
from a few cells, passes through a multicellular tumor spheroid (MTS) stage (Figure
3) and proceeds to the macroscopic stages at clinically designated time-points for a
virtual patient: detectable lesion, diagnosis and death. This 4D CA algorithm models
macroscopic GBM tumors as an enormous idealized MTS, mathematically described by
a Gompertz-function given by Eq. (1), since this tumor, like a large MTS, comprises
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large areas of central necrosis surrounded by a rapidly expanding shell of viable cells
(Figure 2). In accordance with experimental data, the algorithm also implicitly takes
into account that invasive cells are continually shed from the tumor surface and implicitly
assumes that the tumor mass is well-vascularized during the entire process of growth.
The effects of vasculature evolution are considered explicitly in Sections 5 and 7.
3.1. A 4D Cellular Automaton Model
A CA model is a spatially and temporally discrete model that consists of a grid of cells,
with each cell being in one of a number of predefined states. The state of a cell at
a given point in time depends on the state of itself and its neighbors at the previous
discrete time point. Transitions between states are determined by a set of local rules.
The simulation is designed to predict clinically important criteria such as the fraction
of the tumor which is able to divide (GF), the non-proliferative (G0/G1 arrest) and
necrotic fractions, as well as the rate of growth (volumetric doubling time) at given
radii. Furthermore, this CA model enables one to study emergence of a subpopulation
due to cell mutations as well as the effects of tumor treatment and resistance. The
general CA model includes both a proliferation routine which models tumor growth by
cell division and a treatment routine which models the cell response to treatment and cell
mutations. It also incorporates a novel adaptive automaton cell generation procedure.
In particular, the CA model is characterized by several biologically important features:
• The model is able to grow the tumor from a very small size of roughly 1000 real
cells through to a fully developed tumor with 1011 cells. This allows a tumor to be
grown from almost any starting point, through to maturity.
• The thickness of different tumor layers, i.e. the proliferative rim and the non-
proliferative shell, are linked to the overall tumor radius by a 2/3 power relation.
This reflects a surface area to volume ratio, which can be biologically interpreted
as nutrients diffusing through a surface.
• The discrete nature of the model and the variable density lattice allow us to
control the inclusion of mutant “hot spots” in the tumor as well as variable cell
sensitivity/resistance to treatment. The variable density lattice will allow us to
look at such an area at a higher resolution.
• Our inclusion of mechanical confinement pressure enables us to simulate the
physiological confinement by the skull at different locations within the brain
differently.
Our CA algorithm can be broken into three parts: automaton cell generation, the
proliferation routine and the treatment routine. In the ensuing discussions, we first
present the three parts of our algorithm. Then we show that the our model reflects
a test case derived from the medical literature very well, proving the hypothesis that
macroscopic tumor growth behavior may be modeled with primarily microscopic data.
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3.1.1. Cellular Automaton Cell Generation The first step of the simulation is to
generate the automaton cells. The underlying lattice for the algorithm is the Delaunay
triangulation, which is the dual lattice of the Voronoi tessellation [11, 62]. In order to
develop the automaton cells, a prescribed number of random points are generated in
the unit square using the process of random sequential addition (RSA) of hard circular
disks. In the RSA procedure, as a random point is generated, it is checked if the point
falls within some prescribed distance from any other point already placed in the system
[11, 62]. Points that fall too close to any other point are rejected, and all others are
added to the system. Each cell in the final Voronoi lattice will contain exactly one
of these accepted sites. The Voronoi cell is defined by the region of space nearer to
a particular site than any other site. In two-dimensions, this results in a collection of
polygons that fill the plane.
Figure 4: Voronoi Cells
Because a real brain tumor grows over several orders of magnitude in volume, the
lattice was designed to allowed continuous variation with the radius of the tumor. The
density of lattice sites near the center was significantly higher than that at the edge. A
higher site density corresponds to less real cells per automaton cell, and so to a higher
resolution. The higher density at the center enables us to simulate the flat small-time
behavior of the Gompertz curve. In the current model, the innermost automaton cells
represent roughly 100 real cells, while the outermost automaton cells represent roughly
106 real cells. The average distance between lattice sites was described by the following
relation:
ζ =
1
6
r2/3 (2)
in which ζ is the average distance between lattice sites and r is the radial position
at which the density is being measured. This relation restricts the increase in the
number of proliferating cells as the tumor grows. Note that when modeling the effects
of vasculature evolution discussed in the following, a a uniform lattice is used for which
each automaton cell includes approximately 10 real cancer cells.
Figure 5: Idealized tumor
3.1.2. Minimalist 4D Proliferation Algorithm The proliferation algorithm is designed
to allow a tumor consisting of a few automaton cells, representing roughly 1000 real
cells, to grow to a full macroscopic size. An idealized model of a macroscopic tumor
is an almost spherical body consisting of concentric shells of necrotic, non-proliferative
and proliferative regions (see Figure 5). The four microscopic growth parameters of
the algorithm are p0, a, b, and Rmax reflecting, respectively, the rate at which the
proliferative cells divide, the nutritional needs of the non-proliferative and proliferative
cells, and the response of the tumor to mechanical pressure within the skull. In addition,
there are four key time-dependent quantities that determine the dynamics of the tumor,
i.e., Rt, δp, δn, pd giving, respectively, the average overall tumor radius, proliferative
rim thickness, non-proliferative thickness and probability of division. These quantities
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Table 1. The time-dependent functions and growth, treatment parameters for the
model.
Functions within the model (time dependent)
Rt Average overall tumor radius (see Appendix)
δp Proliferative rim thickness (determines growth fraction)
δn Non-proliferative thickness (determines necrotic fraction)
pd Probability of division (varies with time and position)
Growth parameters
p0 Base probability of division, linked to cell-doubling time (0.192)
a Base necrotic thickness, controlled by nutritional needs (0.42 mm1/3)
b Base proliferative thickness, controlled by nutritional needs (0.11 mm1/3)
Rmax Maximum tumor extent, controlled by pressure response (38 mm)
are based on the four parameters (p0, a, b, Rmax) and are calculated according to the
following algorithm.
• Initial setup: The cells within a fixed initial radius of the center of the grid are
designated proliferative. All other cells are designated as non-tumorous.
• Time is discretized and incremented, so that at each time step:
– Each cell is checked for type: non-tumorous or (apoptotic and) necrotic, non-
proliferative or proliferative tumorous cells.
– Non-tumorous cells and tumorous necrotic cells are inert.
– Non-proliferative (growth-arrested) cells more than a certain distance, δn, from
the tumor’s edge are turned necrotic. This is designed to model the effects of
a nutritional gradient. The edge of the tumor is taken to be the nearest non-
tumorous cell, i.e.,
δn = aR
2/3
t . (3)
– Proliferative cells are checked to see if they will attempt to divide according
to the probability of division, pd, which is influenced by the location of the
dividing cell, reflecting the effects of mechanical confinement pressure. This
effect requires the use of an additional parameter, the maximum tumor extent,
Rmax. pd is given by
pd = p0(1−
r
Rmax
) (4)
– If a cell attempts to divide, it will search for sufficient space for the new
cell beginning with its nearest neighbors and expanding outwards until either
an empty (non-tumorous) space is found or nothing is found within the
proliferation radius, δp. The radius searched is calculated as:
δp = bR
2/3
t . (5)
Toward an Ising Model of Cancer and Beyond 11
– If a cell attempts to divide but cannot find space it is turned into a non-
proliferative cell.
• After a predetermined amount of time has been stepped through, the volume and
radius of the tumor are plotted as a function of time.
• The type of cell contained in each grid are saved at given times.
Figure 6: An illustration of the proliferation algorithm.
The above simulation procedure is also illustrated in Figure 6. We note that
the redefinition of the proliferative to non-proliferative transition implemented in the
algorithm is one of the most important new features of the model. They allow a larger
number of cells to divide, since cells no longer need to be on the outermost surface of
the tumor to divide. In addition, it ensured that cells that cannot divide are correctly
labeled as such. Table 1 summarizes the important time-dependent functions calculated
by the proliferation algorithm and the constant growth parameters used. The readers
are referred to Ref. [11] for the detailed description of the algorithm and parameters.
3.1.3. Extending the 4D CA Model to Study Emergence of a Subpopulation Malignant
brain tumors such as GBM generally consist of a number of distinct subclonal
populations. Each of these subpopulations, arising from the constant genetic and
epigenetic alteration of existing cells in the rapidly growing tumor, may be characterized
by its own behaviors and properties. However, since each single cell mutation only leads
to a small number of offspring initially, very few newly arisen subpopulations survive
more than a short time. Kansal et al [12] have extended the CA to quantify “emergence,”
i.e. the likelihood of an isolated subpopulation surviving for an extended period of time.
Only mutations affecting the rate of cellular division were considered in this rendition of
the model. In addition, only competition between clones was taken into account; there
were no cooperative effects included, although such effects can easily be incorporated.
The simulation procedure is as follows: an initial tumor composed entirely of cells
of the primary clonal population is introduced, which is allowed to grow using the
proliferation algorithm until it reaches a predetermined average overall radius. Then,
a single (or a small number of) automaton cell is changed from the primary strain to
a secondary strain with an altered probability of division, which represents very small
fractions of the total population of proliferative tumor cells and the tumor is allowed
to continue to grow using the proliferation algorithm. It is important to note that this
does not represent a single mutation event but rather a mutation event that results in
a subpopulation reaching a size dictated by the limits of the lattice resolution employed
(i.e., a specified number of cells).
The behavior of the secondary strain was characterized in terms of two properties:
the degree α and the relative size β of the initial population of mutated cells, i.e.,
α =
p1
p0
, (6)
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which represents the ratio between the base probability of division of the new clone, p1,
and that of the original clone, p0; and
β =
volume of proliferating cells of the new clone
volume of proliferating cells of the original clone
. (7)
Positive, negative and no competitive advantages are respectively conferred for α > 1,
α < 1, and α = 1. The initial value β, i.e., β0 = β(t = 0), is a parameter of the model
reflecting the size of the mutated region introduced.
3.1.4. Extending the 4D CA Model to Study Treatment Besides the four growth
parameters in the minimalist 4D CA model, three additional parameters for treatment
were subsequently introduced: γ, ǫ, and φ, the values of which reflect, respectively, the
proliferative cells’ treatment sensitivity, the non-proliferative cells’ treatment sensitivity,
and the mutational response of the tumor cells to treatment [13]. Furthermore, there
are three additional time-dependent quantities Dpro, Dnon and β, giving respectively
fraction of proliferative cells that die upon treatment (equivalent to γ), fraction of
non-proliferative cells that die upon treatment (equivalent to γǫ) and volume fraction
of mutated living cells. These parameters are summarized in Table 2 and a detailed
discussion is given in Ref. [13].
Table 2. Treatment parameters and associated terms for the model.
Treatment parameters
γ Governs the proliferative cells’ response at each
instance of treatment (0.55− 0.95)
ǫ Allows for different treatment responses between
proliferative and non-proliferative cells (0− 0.4)
φ Fraction of surviving proliferative cells
that mutate in response to treatment (10−5 − 10−2)
Other Terms
Dpro Fraction of proliferative cells that die
upon treatment; equivalent to γ
Dnon Fraction of non-proliferative cells that die
upon treatment; equivalent to γǫ
β Volumetric fraction of living cells (proliferative and
non-proliferative) belonging to the secondary strain
In the simulation, treatment was introduced as “periodic impulse”, i.e., a small
tumor mass is introduced which is intended to represent a GBM after successful surgical
resection and allowed to grow using the proliferation algorithm; then treatment is
applied and considered effective at discrete time points. In particular, the simulation
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proceeds through the proliferative steps until every nw week time-point, at which time
the treatment routine is introduced:
• After the last round of cellular division, each proliferative cell is checked to see if
it is killed by the treatment. The probability of death for a given proliferative cell
Dpro is given by
Dpro = γ, (8)
where γ ∈ (0, 1) is the proliferative treatment parameter. Dead proliferative
automaton cells are converted to healthy cells.
• Each non-proliferative cell is checked to see if it is killed. The probability of death
for a given non-proliferative cell Dnon is given by
Dnon = γǫ, (9)
where ǫ ∈ (0, 1) is the non-proliferative treatment parameter and Dnon is a fraction
of Dpro. A non-proliferative cell is converted to a necrotic cell upon death.
• Each surviving non-proliferative cell is checked to see if it is within the proliferative
thickness of a healthy cell (i.e. the tumor surface). If so, the non-proliferative cell
is converted back to a proliferative cell.
• All proliferative cells (including newly-designated ones) are checked for mutations
for treatment resistance γ with probability φ. A new γ ∈ (0, 1) is randomly
generated for mutated cells while ǫ remains constant.
Clinically, GBM treatment consists of both radiation therapy and chemotherapy.
However, in our model we do not distinguish between the separate effects of these two
methods. The tumors’ response to all treatment is captured by the treatment algorithm.
Moreover, this response is assumed to be instantaneous at each four-week time point.
4. Putting the 4D CA Model Through Its Paces
4.1. A Test Case for Proliferation Algorithm
The tumor growth data generated via the minimalist 4D CA proliferation algorithm
was compared with available experimental data for an untreated GBM tumor from the
medical literature [11]. The parameters compared were cell number, growth fraction,
necrotic fraction and volumetric doubling time, which are used to determine a tumor’s
level of malignancy and the prognosis for its future growth. Because it is impossible to
determine the exact time a tumor began growing, the medical data are listed at fixed
radii. The different cell fractions used were extrapolated from the spheroid level and
compared to data published for cell fractions at macroscopic stages.
Summarized in Table 3 is the comparison between simulation results and data
(experimental, as well as clinical) taken from the medical literature (see Ref. [11] for
detailed references). The simulation data were created using a tumor which was grown
from an initial radius of 0.1 mm. The following parameter set (see Table 1) was used:
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Table 3. Comparison of simulated tumor growth and experimental data. For each
quantity, the simulation data is give on the first line and the experimental data is given
on the second line.
Spheroid Det. Les. Diagnosis Death
Time Day 69 Day 223 Day 454 Day 560
Radius 0.5 mm 5 mm 18.5 mm 25 mm
0.5 mm 5 mm 18.5 mm 25 mm
Cell No. 106 109 5× 1010 1011
7× 105 6× 108 4× 1010 9× 1010
Growth fraction 0.36 0.30 0.20 0.09
0.35 0.30 0.18 0.11
Necrotic fraction 0.46 0.49 0.55 0.60
0.38 0.53 0.58 0.63
Volume-doubling time 6 days 45 days 70 days 105 days
9 days 36 days 68 days 100 days
p0 = 0.192, a = 0.42 mm
1/3, b = 0.11 mm1/3, Rmax = 37.5 mm
This value of p0 corresponds to a cell-doubling time of 4.0 days. The parameters a
and b have been chosen to give a growth history that quantitatively fits the test case.
The specification of these parameters corresponds to the specification of a clonal strain.
The parameter Rmax was similarly chosen to match the test case history. In this case,
however, the fit is relatively insensitive to the value of Rmax, as long as the parameter is
somewhat larger than the fatal radius in the test case. On the whole, the simulation data
reproduces the test case very well. The virtual patient would die roughly 11 months after
the tumor radius reached 5 mm and 3.5 months after the expected time of diagnosis.
The fatal tumor volume is about 65 cm3.
Figure 7: Cross-sections of a Growing Mono-Clonal Tumor.
Figure 8: A cut-away view of the simulated tumor.
Figure 9: The Volume and Radius of the Developing Tumor.
Central cross-sections of the tumors are shown in Figure 7, in which the growth
of the tumor can be followed graphically over time. Here necrotic cells are labeled
with black, non-proliferative tumorous cells with light gray and proliferative tumor cells
with dark gray. A cut-away view of the simulated tumor is shown in Figure 8. As
expected in this idealized case, the tumor is essentially spherical, within a small degree
of randomness. The high degree of spherical symmetry ensures that the central cross-
section is a representative view. The volume and radius of the developing tumor are
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shown versus time in Figure 9. Note that the virtual patient dies while the untreated
tumor is in the rapid growth phase.
4.2. Modeling the Emergence of A Subpopulation
Recall that the parameter α reflects the degree of advantage of the mutated
subpopulation over the primary clone (positive, negative and no competitive advantages
are respectively conferred for α > 1, α < 1, and α = 1) and the initial value β, i.e.,
β0 = β(t = 0), is a parameter of the model reflecting the size of the mutated region
introduced. A subpopulation is considered to have emerged once it comprises 5% of the
actively dividing cell population or if it remains in the actively dividing state once the
tumor has reached a fully developed size. Numerous simulations (at least 100) were run
at each parameter set by Kansal et al [12] in order to calculate the expected probabilities
of emergence, i.e.,
P =
number of trials in which emergence occurs
total number of trials
. (10)
along with confidence intervals, σ, defined as
σ =
√
p(1− p)
N
(11)
where p represents the observed probability of emergence in N trials. We note that the
probability of emergence is actually a conditional probability: it is the probability that
a subpopulation with a mutation of degree α emerges given that a region of relative size
β0 has mutated.
Figure 10: P vs. alpha and cut-away view of simulated tumor with a subpopulation.
The results represented were run with a parameter set in which
p0 = 0.192, p1 = αp0, a = 0.42 mm
1/3,
b = 0.11 mm1/3, Rmax = 37.5 mm
for the primary strain, in a simulation in which each time step represents one day
[12]. Figure 10 depicts the observed probability of emergence, P , for a subpopulation
of initial size β0 = 6 × 10
−5 as a function of α, which gives an approximation of the
true, asymptotic, probability of emergence. Also shown in Figure 10 is a cut-away view
of the simulated tumor with a subpopulation. Not surprisingly, P is a monotonically
increasing function that tends to 0 for α < 1 and to 1 as α become significantly greater
than 1.
Perhaps the most striking feature of these results is that there is a non-zero
probability of emergence for a very small population with no growth rate advantage,
or even with a small disadvantage (i.e. α ≈ 0.95). This suggests that a mutated
subpopulation may arise even without any growth advantage. These populations could
represent “dormant” clones which confer an advantage not being selected for at the time.
An example would be the appearance of hypoxia tolerant or even treatment resistant
clones. It should be stressed that populations with less competitive advantages over
other tumor strains can have a nonzero probability of emergence especially if they are
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localized in space, which leads to a minimum surface area between the two populations
per unit tumor volume. In this way, the population with smaller competitive advantage
can compete more effectively. We will see in the next subsection that this same
principle is at work when resistance is induced due to treatment. It was also found
that the emergence probability P is a monotonically increasing function in β0 and has
a logarithmic dependence on β0 [12].
Figure 11: Effects of the subpopulation on the tumor geometry.
Figure 12: Effects of the subpopulation on growth history.
Figure 11 shows the effects of growth of the subpopulation on the tumor geometry.
It can be seen clearly that the center of mass of the tumor is significantly shifted by the
emergence of the subpopulation. Another example of the importance of subpopulations
is depicted in Figure 12 [12]. In this example, a diagnosis was made (on day t0)
giving information about the macroscopic size and growth rate of the tumor. From this
information three possible growth histories of the tumor are plotted. One is the time
history of the tumor with an emergent subpopulation. The others represent limiting
cases, each with a monoclonal tumor of either the primary (“base p0”) or secondary
(“high p0”) clonal strain. Note that at the time of diagnosis all three scenarios have
very similar dynamics. So any of the three histories is a reasonable prediction given
only size and growth rate information. However, estimating a fatal tumor volume to be
65 cm3 and defining the survival time to be the time required to reach this volume, the
base case mis-predicts survival times to be 90 days, which is 30 days more than the 60
days of the “true” course.
It is noteworthy that from this perspective the overall future growth dynamics
of the entire tumor closely follows that of the most aggressive case, indicating that
the more aggressive clone dominates overall outcome and should therefore also define
the appropriate treatment. This finding supports the current practice in pathology
of grading tumors according to the most malignant area (i.e. population) found in
any biopsy material. Although of less clinical significance, the high case similarly mis-
predicts the past history of the tumor. If the diagnosis had been made earlier, the
base case would yield still worse future predictions. Similarly the “high” p0 case would
yield worse past predictions for a diagnosis made at a later time. The predictive errors
arising from the assumption of a monoclonal tumor indicate how important an accurate
estimate of the clonal composition of a tumor is in establishing a complete history and
prognosis. Note that the numbers given here are intended to show the scale of the
inaccuracy possible, not to reflect any data extracted from actual patients.
4.3. Modeling the Effects of Tumor Treatment and Resistance
Combining the proliferation algorithm and the treatment algorithm, the behavior
of tumors that are able to develop resistance throughout the course of treatment
were investigated [13]. Recall that additional parameters were introduced in the
treatment routine: γ, ǫ, and φ, the values of which reflect, respectively, the proliferative
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cells’ treatment sensitivity, the non-proliferative cells’ treatment sensitivity, and the
mutational response of the tumor cells to treatment (see Table 2).
These investigation consisted of three individual case studies. In Case 1, the growth
dynamics of monoclonal tumors are studied to determine how tumor behavior is affected
by the treatment parameters γ and ǫ. Case 2 builds upon this information, analyzing
the behavior of two-strain tumors. Here, a secondary treatment-resistant strain
exists alongside a primary treatment-sensitive strain. A secondary sub-population was
introduced at the onset of each simulation, initializing it in different spatial arrangements
and at several (small) relative volumes. In both Cases 1 and 2, no additional sub-
populations arise in the tumors once the simulation has begun (i.e. φ = 0). In Case
3, however, tumors were studied that were capable of undergoing resistance mutations
in response to each round of treatment (φ > 0). In these simulations, the growth and
morphology of the tumors were analyzed in relation to the fraction of mutating cells.
Here we only report on the results of Cases 2 and 3. In Case 2, the
smaller subpopulation of a secondary treatment-resistant strain was initially spatially
distributed in two different ways on the tumor surface that primarily consist of the
primary treatment-sensitive strain: a localized and scattered scenario, reflecting possible
effects of the result of surgery, for example (see Figure 13). In the simulation, the tumors
were initialized as a single strain, i.e., monoclonally with γ = 0.95 and ǫ = 0.05 and
treatment was introduced every four weeks while the tumor is growing from a small mass
with a radius of 4mm, corresponding to approximately 99% of surgical volume resection.
For the scattered resistance scenario, the resistant strain was found to compete more
effectively with the sensitive strain and it was shown that the initial number of resistant
cells were not a significant indicator or prognosis.
Figure 13: Spatial distributions of the resistance strain.
These conclusions may at first glance seem to contradict the those reported by by
Kansal et al [12]. Recall that in this work the selection pressure was different (growth-
rate competition versus treatment effects). Moreover, the roles of the primary and
secondary strains are reversed in the Case 2 example: the primary strain possessed
a competitive advantage over the secondary strain. Nevertheless, the conclusions of
both papers [12, 13] follow precisely the same principle. The proliferative ability of a
strain with a competitive advantage varies directly with its contact area with the less
comptetive strain per cell.
Unlike Case 2, the tumors in Case 3 begin the simulations as a single strain. Here,
however, treatment can induce the appearance of mutant strains (φ > 0). In these
simulations, the growth and morphology of the tumors were analyzed in relation to the
fraction of mutating cells. The tumors in Case 3 are all initialized monoclonally with
γ = 0.95 and ǫ = 0.05. With this initial γ-value, nearly every mutant strain that arises
from the initial population will posses a lower γ-value. This is not to suggest that all
induced mutations must possess increased resistance. This fact here merely stems from
the initial sensitive tumor under consideration.
At first, the tumors in Case 3 will develop like treatment-sensitive, monoclonal
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tumors; growth will then accelerate as resistant cells begin to dominate. This
corresponds to a case of acquired resistance via induced (genetic and epigenetic)
mutations. Overall, the tumor dynamics here are more variable than in Cases 1 and 2.
When a new strain appears, it begins as a single automaton cell. Unlike Case 2, not all
new strains will be able to proliferate to an appreciable extent. Some are overwhelmed
by the parent strain from which they arise.
The mean survival time of the tumors were determined as a function of φ and these
data are summarized in Figure 14. plots this data; From φ = 10−5 to φ = 10−2, the
survival times vary nearly logarithmically with φ. When φ = 10−5, the mean time is near
27 months, as most tumors remain monoclonal (or nearly monoclonal) with γ = 0.95,
ǫ = 0.05. As φ increases, resistant strains appear more commonly and survival times
fall.
Figure 14: Survival times associated with continuously mutating tumors.
One of the more intriguing observations in this case involves the gross morphology
of the mutating tumors. Their three-dimensional geometries exhibit an interesting
dependence on the value of φ. Figure 15 presents representative images of the fully-
developed tumors for small, intermediate and large fractions of mutated proliferative
cells φ after treatment. For small φ (left panel of Figure 15), some tumors develop a
secondary strain while others do not. The tumors that remain monoclonal maintain their
spherical geometry. When a resistant sub-population does develop, it appears as a lobe
on the parental tumor. For intermediate φ, resistant sub-populations consistently arise
from the parental strain. The middle panel of Figure 15 depicts a typical tumor, whose
geometries consistently deviate from an ideal sphere. These tumors are multi-lobed in
appearance, and the original strain is commonly overwhelmed. However, when φ is large,
the geometric trend reverses, i.e., the tumors (right panel of Figure 15) again appear
more spherical, despite the fact that they experience the greatest fraction of mutations
per treatment event. These images suggest that extreme mutational responses can lead
to similar macroscopic geometries. Non-spherical geometries result from intermediate
φ-values.
Figure 15: Images of continuously mutating tumors.
5. Modeling the Effects of Vasculature Evolution
As pointed out in the Introduction, there are complex interactions occurring between
between a tumor and the host environment, which makes it very difficult in predicting
clinical outcome, even if mutations responsible for oncogenesis that determine tumor
growth are beginning to be understood. These interactions include the effects of
vasculature evolution on tumor growth, the organ-imposed physical confinement as well
as the host heterogeneity. While the three studies described in the previous section
were successful at analyzing and characterizing GBM growth both with and without
treatment, in each case, the CA model made the simplifying assumption that the
tumor mass was well-vascularized (the vascular network and angiogenesis were implicitly
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accounted for) and the effects of mechanical confinement were limited to one parameter
(Rmax), which allowed for growth of spherically symmetric tumors with a maximum
radius. Spherical-like growth is realistic provided that the environment is effectively
homogeneous, but heterogeneous environments will cause apsherically-shaped tumors.
In order to incorporate a greater level of microscopic detail, a 3D (two dimensions in
space and one in time) hybrid variant of the original CA model that allows one to study
how changes in the tumor vasculature due to vessel co-option, regression and sprouting
influence GBM was developed by Gevertz and Torquato [18]. This computational
algorithm is based on the co-option-regression-growth experimental model of tumor
vasculature evolution [29, 56]. In this model, as a malignant mass grows, the tumor
cells co-opt the mature vessels of the surrounding tissue that express constant levels
of bound angiopoietin-1 (Ang-1). Vessel co-option leads to the upregulation of the
antagonist of Ang-1, angiopoietin-2 (Ang-2). In the absence of the anti-apoptotic signal
triggered by vascular endothelial growth factor (VEGF), this shift destabilizes the co-
opted vessels within the tumor center and marks them for regression [29, 56]. Vessel
regression in the absence of vessel growth leads to the formation of hypoxic regions in
the tumor mass. Hypoxia induces the expression of VEGF, stimulating the growth of
new blood vessels.
A system of reaction-diffusion equations was developed to track the spatial and
temporal evolution of the aforementioned key factors involved in blood vessel growth and
regression [18] (see Section 6 for a detailed description). Based on a set of algorithmic
rules, the concentration of each protein and bound receptor at a blood vessel determines
if a vessel will divide, regress or remain stagnant. The structure of the blood vessel
network, in turn, is used to estimate the oxygen concentration at each cell site. Oxygen
levels determine the proliferative capacity of each automaton cell. The reader is referred
to [18] for the full details of this algorithm. The model proved to quantitatively
agree with experimental observations on the growth of tumors when angiogenesis is
successfully initiated and when angiogenesis is inhibited. Further, due to the biological
details incorporated into the model, the algorithm was used to explore tumor response
to a variety of single and multimodal treatment strategies [18].
6. Modeling the Effects of Physical Confinement and Heterogeneous
Environment
An assumption made in both the original CA algorithm and the one that explicitly
incorporates vascular evolution is that the tumor is growing in a spherically symmetric
fashion. In a study performed by Helmlinger et al [63], it was shown that neoplastic
growth is spherically symmetric only when the environment in which the tumor
is developing imposes no physical boundaries on growth. In particular, it was
demonstrated that human adenocarcinoma cells grown in a 0.7% gel that is placed in a
cylindrical glass tube develop to take on an ellipsoidal shape, driven by the geometry of
the capillary tube. However, when the same cells are grown in the same gel outside the
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capillary tube, a spherical mass develops [63]. This experiment clearly highlights that
the assumption of radially symmetric growth is only valid when a tumor grows in an
unconfined or spherically symmetric environment.
Since many organs, including the brain and spinal cord, impose non-radially
symmetric physical confinement on tumor growth, the original CA algorithm was
modified to incorporate boundary and heterogeneity effects on neoplastic progression
[20]. The first modification that was made to the original algorithm was simply to specify
and account for the boundary that is confining tumor growth. Several modifications
were made to the original automaton rules to account for the impact of this boundary
on neoplastic progression. The original CA algorithm imposed radial symmetry in
order to determine whether a cancer cell is proliferative, hypoxic, or necrotic. The
assumption of radially symmetric growth was also utilized in determining the probability
a proliferative cell divides. In order to allow tumor growth in any confining environment,
all assumptions of radial symmetry from the automaton evolution rules were removed.
It was demonstrated that models that do not account for the geometry of the confining
boundary and the heterogeneity in tissue structure lead to inaccurate predictions on
tumor size, shape and spread (the distribution of cells throughout the growth-permitting
region). The readers are referred to Ref. [20] for the details of this investigation, but
an illustration of confinement effects are given in the next section.
7. A Merged Tool for Growing Heterogeneous Tumors In Silico
7.1. Algorithmic Details
Each of the previously discussed algorithms were designed to answer a particular set
of questions and successfully served their purpose. Hence, Gevertz and Torquato
[21] merged each algorithm into a single cancer simulation tool that would not only
accomplish what each individual algorithm had accomplished, but had the capacity to
have emergent properties not identifiable prior to model integration. In developing the
merged algorithm, some modifications were made to the original automaton rules to
more realistically mimic tumor progression. The merged simulation tool is summarized
as follows:
(i) Automaton cell generation: A Voronoi tessellation of random points generated
using the nonequilibrium procedure of random sequential addition of hard disks
determines the underlying lattice for our algorithm [11, 62]. Here a uniform density
lattice is used instead of the lattice with variable density. Each automaton cell
created via this procedure represents a cluster of a very small number of biological
cells (∼ 10).
(ii) Define confining boundary: Each automaton cell is divided into one of two
regimes: nonmalignant cells within the confining boundary and nonmalignant cells
outside of the boundary.
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(iii) Healthy microvascular network: The blood vessel network which supplies the
cells in the tissue region of interest with oxygen and nutrients is generated using
the random analog of the Krogh cylinder model detailed in Ref. [18]. One aspect
of the merger involved limiting blood vessel development to the subset of space in
which tumor growth occurs.
(iv) Initialize tumor: Designate a chosen nonmalignant cell inside the growth-
permitting environment as a proliferative cancer cell.
(v) Tumor growth algorithm: Time is then discretized into units that represent one
real day. At each time step:
(a) Solve PDEs : A previously-developed system of partial differential equations
[18] is numerically solved one day forward in time. The quantities that
govern vasculature evolution, and hence are included in the equations, are
concentrations of VEGF (v), unoccupied VEGFR-2 receptors (rv0), the
VEGFR-2 receptor occupied with VEGF (rv), Ang-1 (a1), Ang-2 (a2), the
unoccupied angiopoietin receptor Tie-2 (ra0), the Tie-2 receptor occupied with
Ang-1 (ra1) and the Tie-2 receptor occupied with Ang-2 (ra2). The parameters
in these equations include diffusion coefficients of protein x (Dx), production
rates bx and bx, carrying capacities Kx, association and dissociation rates (ky
and k
−y) and decay rates µx. Any term with a subscript i denotes an indicator
function; for example, pi is a proliferative cell indicator function. It equals 1
if a proliferative cell is present in a particular region of space, and it equals
0 otherwise. Likewise, hi is the hypoxic cell indicator function, ni is necrotic
cell indicator function and ei is the endothelial cell indicator function. The
equations solved at each step of the algorithm are:
∂v
∂t
= Dv∆v + bvhi(h− v
2/Kv)− k0vrv0 + k−0rv − µvv (12)
∂a1
∂t
= ba1ei(pi+hi+ni)(e0−a
2
1
/Ka)−k1a1ra0+k−1ra1−µa1a1(13)
∂a2
∂t
= Da2∆a2 + ba2ei(pi + hi + ni)(e0 − a
2
2
/Ka)
+ba2hi(h− a
2
2
/Ka)− k2a2ra0 + k−2ra2 − µa2a2
(14)
∂rv0
∂t
= −k0vrv0 + k−0rv (15)
∂ra0
∂t
= −k1a1ra0 + k−1ra1 − k2a2ra0 + k−2ra2 (16)
∂rv
∂t
= k0vrv0 − k−0rv (17)
∂ra1
∂t
= k1a1ra0 − k−1ra1 (18)
∂ra2
∂t
= k2a2ra0 − k−2ra2 (19)
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In these equations, h(x, y, t) represents the concentration of hypoxic cells and
e0 represents the endothelial cell concentration per blood vessel. The system
of differential equations contains 21 parameters, 13 of which were taken from
experimental data. Parameters were unable to be found in the literature were
estimated. For more details on the parameter values, as well as information
on the initial and boundary conditions and the numerical solver, the reader is
referred to Ref [18].
(b) Vessel Evolution: Check whether each vessel meets the requirements for
regression or growth. Vessels with a concentration of bound Ang-2 six times
greater than that of bound Ang-1 regress [57], provided that the concentration
of bound VEGF is below its critical value. Vessel tips with a sufficient amount
of bound VEGF sprout along the VEGF gradient.
(c) Nonmalignant Cells : Healthy cells undergo apoptosis if vessel regression causes
its oxygen concentration to drop below a critical threshold (more particularly,
if the distance of a healthy cell from a blood vessel exceeds the assumed
diffusion length of oxygen, 250 µm ). Further, nonmalignant cells do not
divide in the model. While nonmalignant cell division occurs in some organs,
a hallmark of neoplastic growth is that tumor cells replicate significantly
faster than the corresponding normal cells. Hence, we work under the
simplifying assumption that nonmalignant division rates are so small compared
to neoplastic division rates that they become relatively unimportant in the
time scales being considered. In the cases where this assumption does not
hold, nonmalignant cellular division would have to be incorporated into the
model.
(d) Inert Cells : Tumorous necrotic cells are inert. This assumption is certainly
valid for the tumor type that motivated this modeling work, glioblastoma
multiforme. In the case of glioblastoma, the presence of necrosis is an important
diagnostic feature and, in fact, negatively correlates with patient prognosis.
(e) Hypoxic Cells : A hypoxic cell turns proliferative if its oxygen level exceeds
a specified threshold [18] and turns necrotic if the cell has survived under
sustained hypoxia for a specified number of days. In the original algorithms,
the transition from hypoxia to necrosis was based on an oxygen concentration
threshold. However, given that cells (both tumorous and nonmalignant alike)
have been shown to have a limited lifespan under sustained hypoxic conditions,
a temporal switch more accurately describes the hypoxic to necrotic transition.
Thus, a novel aspect of the merged algorithm is a temporal hypoxic to necrotic
transition. It has been measured that human tumor cells remain viable in
hypoxic regions of a variety of xenografts for 4-10 days [18]. In our simulations,
we will use the upper-end of this measurement and assume that tumor cells
can survive under sustained hypoxia for 10 days.
(f) Proliferative Cells : A proliferative cell turns hypoxic if its oxygen level drops
below a specified threshold. However, if the oxygen level is sufficiently high,
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the cell attempts to divide into the space of a viable nonmalignant cell in the
growth-permitting region. The probability of division pdiv is given by:
pdiv = p0(1− r/Lmax) (20)
where p0 is the base probability of division, r is the distance of the dividing
cell from the geometric center of the tumor and Lmax is the distance between
the closest boundary cell in the direction of tumor growth and the tumor’s
center. In the original implementations of the algorithm, p0 was fixed to be
0.192, giving a cell-doubling time of ln(2)/ ln(1 + p0) ≈ 4 days. In the merged
algorithm proposed here, we wanted to account for fact that tumor cells with
a higher oxygen concentration likely have a larger probability of dividing than
those with a lower oxygen concentration. For this reason, we have modified
the algorithm so that p0 depends on the distance to the closest blood vessel
dvessel (which is proportional to the oxygen concentration at a given cell site).
The average value of p0 was fixed to be 0.192, and we have specified that p0
takes on a minimum value pmin of 0.1 and a maximum value pmax of 0.284.
This means that a proliferative cell in the model can have a cell doubling time
anywhere in the range of three to seven days. The formula used to determine
p0 is
p0 =
pmin − pmax
DO2
dvessel + pmax, (21)
where DO2 is the diffusion length of oxygen, taken to be 250 µm [20, 18]. Both
pmin and pmax depend on the average probability of division. If this average
probability changes, so does pmin and pmax.
(g) Tumor Center and Area: After each cell has evolved, recalculate the geometric
center and area of the tumor.
The readers are referred to Ref. [21] for more details, including how cell-level
phenotypic heterogeneity is also considered in a similar fashion to the manner done in
Refs [12] and [13].
7.2. Simulating Heterogeneous Tumor Growth
The 3D cancer simulation tool described here was employed to study tumor growth
in a confined environment: a two-dimensional representation of the cranium in space
as a function of time [21]. The cranium is idealized as an elliptical growth-permitting
environment with two growth-prohibiting circular obstacles representing the ventricular
cavities. Tumor growth is initiated in between a ventricular cavity and the cranium
wall. In this setting, we find that the early-time characteristics of the tumor and the
vasculature are not significantly different than those observed when radial symmetry is
imposed on tumor growth. In particular, after 45 days of growth (Figure 16(a)), vessels
associated with the radially symmetric tumor begin to regress and hypoxia results in the
tumor center. Twenty days later (Figure 16(b)), a strong, disordered angiogenic response
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has occurred in the still radially symmetric tumor. Over the next 50 days of growth
(Figure 16(c) and (d)), the disorganized angiogenic blood vessel network continues to
vascularized the growing tumor, but the tumor’s shape begins to deviate from that of
a circle due to the presence of the confining boundary. The patterns of vascularization
observed are consistent with the patterns observed in the original vascular model [18],
suggesting that the merged algorithm maintains the functionality of the original vascular
algorithm.
Figure 16: Tumor growing in a 2D representation of the cranium.
However, if the results of this simulation are compared with those of the
environmentally-constrained algorithm without the explicit incorporation of the
vasculature [20], we find that the merged model responds to the environmental
constraints in a way that is more physically intuitive. In the original environmentally-
constrained algorithm [20], the tumor responds quickly and drastically to the confining
boundary and ventricular cavities. This occurs because the original evolution rules
not only determine the probability of division based on the distance to the boundary,
but also determine the state of a cell based on a measure of its distance to the
boundary. In the merged model which explicitly incorporates the vasculature, the state
of each cell depends on the blood vessel network, and only the probability of division
directly depends on the boundary. For this reason, the merged algorithm exhibits an
emergent property in that it grows tumors that respond more gradually and naturally
to environmental constraints than does the algorithm without the vasculature.
The tumor growth in a two-dimensional irregular region of space that truly allows
the neoplasm to adapt its shape as it grows in time (i.e., a 3D model) was also
investigated by Gevertz et al [20]; see also Gevertz and Torquato [21]. As with the two-
dimensional representation of the cranium in space, an emergent property of the merged
algorithm in which that a more subtle and natural response to the effects of physical
confinement is found occurs. The studies taking into account mutations responsible for
phenotypic heterogeneity have been carried out by Gevertz and Torquato [21], to which
the readers are referred for more details. We note that all the results presented in this
section need to be validated experimentally.
8. Analysis of the Invasion Network: Minimal Spanning Trees
It is well known that cancer cells can break off the main tumor mass and invade healthy
tissue. For many cancers, this process can eventually result in metastases to other
organs. Tumor-cell invasion is a hallmark of glioblastomas, as individual tumor cells
have been observed to spread diffusely over long distances and can migrate into regions
of the brain essential for the survival of the patient [27]. In certain cases, the invading
tumor cells form branched chains (see Figure 3), i.e., tree structures [61]. The brain
offers these invading cells a variety of pathways they can invade along (such as blood
vessel and white fiber tracts), which may be interpreted as the edges of an underlying
graph with the various “resistances” values along these pathways playing the role of
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edge weights. The underlying physics behind the formation of the observed patterns are
only beginning to be understood.
Figure 17: Examples of weighted graph and the resulting minimal spanning tree.
The competition between local and global driving forces is a crucial factor is
determining the structural organization in a wide variety of naturally occurring branched
networks [64, 65, 66]. As an attempt toward a model of the invasive network emanating
from a solid tumor, Kansal and Torquato [61] investigated the impact of a global
minimization criterion versus a local one on the structure of spanning trees. Spanning
trees are defined as a loopless, connected set of edges that connect all of the nodes in the
underlying graph (see Figure 17). In particular, these authors considered the generalized
minimal spanning tree (GMST) and generalized invasive spanning tree (GIST), because
they generally offer extremes of global (GMST) and local (GIST) criteria. Both GMST
and GIST are defined on graphs in which the nodes are partitioned into groups and each
edge has an assigned weight. GMST is refined (relative to that of a spanning tree) such
that the requirement that every node of the graph is included in the tree is replaced
by the inclusion of at least one node from each group with the additional requirement
that the total weight of tree is minimized [67]. GIST can be constructed by growing
a connected cluster of edges by “invading” the remaining the edge with the minimal
weight at its boundary with the requirement of the inclusion of at least one node from
each group in the final tree [61].
Kansal and Torquato [61] have developed efficient algorithms to generate both
GMST and GIST structures, as well as a method to convert GIST structure
incrementally into a more globally optimized GMST-like structure (see Figure 18). The
readers are referred to the original paper for more algorithmic details. These methods
allow various structural features to be observed as a function of the degree to which either
criterion is imposed and the intermediate structures can then serve as benchmarks for
comparison when a real image is analyzed.
Figure 18: Examples of GMST and GIST.
We note that a general procedure by which information extracted from a single,
fixed network structure can be utilized to understand the physical processes which
guided the formation of that structure is highly desirable in understanding the invasion
network of tumor cells, since the temporal development of such a network is extremely
difficult to observe. To this end, Kansal and Torquato [61] examined a variety of
structural characterizations and found that the occupied edge density (i.e., the fraction
of edges in the graph that are included in the tree) and the tortuosity of the arcs in the
trees (i.e., the average of the ratio of the path length between two arbitrary nodes in the
tree and the Euclidean distance between them) correlate well with the degree to which
an intermediate structure resembles the GMST or GIST. Since both characterizations
are straightforward to determine from an image (e.g., only the information of the tree
is required for tortuosity and additional information of underlying graph is needed for
occupied edge density), they are potentially useful tools in the analysis of the formation
of invasion network structures. Once the distribution of the invasive cells in the brain
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is understood, a cellular automaton simulation tool for glioblastoma that is useful in
a clinical setting could be developed. This of course would apply more generally to
invasion networks around other solid tumors.
9. Conclusions and Future Work
In this paper, we have reviewed the work that we have performed to attempt to develop
an Ising model of cancer. We began by describing a minimalist 4D cellular automaton
model of cancer in which healthy cells transition between states (proliferative, hypoxic,
and necrotic) according to simple local rules and their present states, which can viewed as
a stripped-down Ising model of cancer [11, 12, 13]. Using four proliferation parameters,
this model was shown to reflect the growth dynamics of a clinically untreated tumor
very well [11]. This was followed by discussion of an extension of the model to study the
effect on the tumor dynamics and geometry of a mutated subpopulation [12] and how
tumor growth is affected by chemotherapeutic treatment, including induced resistance,
with additional three treatment parameters [13]. An improved CA model that explicitly
accounts for angiogenesis [18] as well as the heterogeneous and confined environment in
which a tumor grows [20] were discussed. A general cancer simulation tool that merges,
adapts and improves all of the aforementioned mechanism into a single CA model was
also presented and applied to simulate the growth the GBM in a vascularized confined
cranium [21]. Finally, we touched on how one might characterize the invasive network
organization (local versus global organization) around a solid tumor using spanning
trees [61]. However, we must move well beyond the improved CA model as well as
other computational models of cancer in order to make real progress on controlling this
dreaded set of diseases.
9.1. The Obvious but Necessary
Formulating theoretical and computational tools that can be utilized clinically to predict
neoplastic progression and propose individualized optimal treatment strategies to control
cancer growth is the holy grail of tumor modeling. Although the development of our
most comprehensive cellular automaton model is potentially a useful step towards the
long-term goal of an Ising model for cancer, numerous complex mechanisms involved in
tumor growth and their interactions needs to be identified and understood in order to
truly achieve this goal.
For example, an effective Ising model of cancer must incorporate molecular-
level information via a better understanding of the cellular origin of the tumor.
Such information might become available if imaging techniques for spatial statistics
of cell/molecular heterogeneity can be developed. This would enable an improved
understanding of invading cancer cells: cell motility, cell-cell communication and
phenotypes of invading cells. Such knowledge is crucial in order to predict the effects of
treatment and tumor recurrence. The incorporation of stem cells, oncogenes and tumor
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suppressor genes in computational models would aid in our understanding of tumor
progression.
In addition, we must quantitatively characterize the biological (host) environment
(i.e., a heterogeneous material/medium) in which cancer evolves, including both the
microstructure and the associated physical properties. For example, a better knowledge
of diffusion and transport of nutrients, drugs, etc. would significantly improve the
accuracy of the model simulating the effects of vasculature evolution and treatment.
Similarly, cell mechanics and mechanical stresses must be understood. In such cases,
imaging of the biological environment over a wide spectrum of length and time scales
will be crucial.
Figure 19: A cartoon of a two-phase medium.
It is important to emphasize that the theory heterogeneous media is a huge field
within the physical sciences that can be brought to bear to better understand the
host heterogeneous microenvironment of cancer and metastases (see Figure 19). For
example, there exist powerful and sophisticated theoretical/computational techniques
to characterize the microstructure of heterogeneous materials and predict their physical
properties [62]. Specifically, the details of complex microstructures are described in
terms of various statistical descriptors (different types of correlation functions), which in
turn determine the physical properties of the heterogeneous materials [62]. In particular,
the effective properties that have been predicted include the diffusion coefficient [68],
reaction rates [69, 70], elastic/viscoelastic moduli [71, 72], thermal conductivity [73],
thermal expansion coefficient [74], fluid permeability [75], and electrical conductivity
[76, 77]. Accurate characterizations of these properties of the host environment and
tumor mass are essential in order to significantly improve models for tumor growth and
invasion. For example, a knowledge of the elastic properties enables one to better model
the effects of physical confinement and the mechanical response of solid tumor; while the
diffusion coefficient and fluid permeability are crucial to model transport of nutrients
and proteins, delivery of drugs and even the migration of cancer cells. These techniques
have been used to propose a novel biologically constrained three-phase model of the
brain microstructure [78].
Given such information, the CA model can be modified accordingly to take into
account the available cell/molecular details of the tumor mass, its invasion network
and the host heterogeneity (e.g., the capillary vasculature and adaptive physical
confinement). Real-time tumor growth and treatment simulations can be carried out
to generate data of clinical utility. For example, instead of only producing data which
qualitatively reflects the general effects of tumor treatment and resistance, one could
use the model to make reliable prognosis and to optimize individual treatment strategy.
It would be fascinating to see if a more refined Ising model for cancer predicted a
“phase transition” phenomenon, which would be in keeping with the behavior of the
standard Ising model for spin systems. For example, it is not hard to imagine that part
of the tumorigenesis process involves a “phase transition” between pre-malignant cells
and malignant cells.
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9.2. Not So Obvious: Optimization and Cancer
We also note that variational principles [62, 79] and optimization techniques [80,
81, 82, 83] have been fruitfully applied to design structures with optimal properties.
Can optimization techniques be applied to understand and control cancer? Although
optimization methods have begun to be employed for such purposes, there full potential
has yet to be realized. For tumor treatment, for example, optimization techniques
could be employed to design chemotherapy/radiation strategies depending on tumor
size, genomic information and the heterogeneous environment as well as the optimal
durations of treatment and rest periods. Given sufficient patient-specific information,
optimized treatment strategies can be designed for individual patients. A variety of
optimization techniques could be brought to bear here, including simulated annealing
methods, and linear and nonlinear programming techniques.
Figure 20: Minimal surface structure
We have developed an optimization methodology that provides a means of
optimally designing multifunctional composite microstructures [81, 83]. We have shown
how the competition between two different performance demands (thermal versus
electrical behaviors or electrical versus mechanical behaviors) results in unexpected
microstructures, namely, minimal surfaces [81, 82] (see Figure 20), which also appear
to optimal for fluid transport [84] as well as diffusion-controlled reactions [85]. This
work suggests that it may be fruitful to explore the development of cancer, which not
only involves competition but cooperation, from a rigorous multifunctional optimization
viewpoint. Cancer processes involve a competition between the primary clone, sub-
clones, healthy tissue, immune system, etc. as well as a cooperation between different
cells types (e.g., stroma cells and cancer cells) in a heterogeneous environment. This
competition/cooperation can be translated into an optimization problem in space and
time. Adaptation of this multifunctional optimization approach to cancer modeling
could provide an alternative to game-theory approaches to understanding cancer [86].
9.3. The Far Out
Figure 21: Diamond and disordered ground state.
Even more challenging and intriguing questions can be asked: Can we exploit the
unique properties of normal stem cells [87] to control cancer (e.g., to deliver therapy to
tumors or to have them compete with the tumor)? Can we use inverse optimization
methods to design “hypothetical” cancers or stem cells with particular the cell-cell
interactions to yield targeted behaviors and then make them in the lab? These “inverse”
problems are motivated by their analog in statistical mechanics [88, 89, 90, 91]. In
statistical mechanics, the “forward problem” is one in which a Hamiltonian (interaction
potential) for a many-body system is specified and then structure of the system and
its thermodynamics are predicted. By contrast, the “inverse” problem of statistical
mechanics seeks to find the “optimal” interaction potential that leads spontaneously
to a novel “targeted” structure (or behavior). We have discovered optimal interaction
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potentials that yield unusual or counterintuitive targeted ground (zero-temperature)
states, e.g., low-coordinated diamond crystal [89] and disordered states [90] with only
isotropic pair potentials (see Figure 21). Ground states are those many-particle
configurations that arise as a result of slowly cooling a liquid to absolute zero
temperature. The aforementioned obtained targeted ground states are so unusual
because much of our experience involves ground states that are highly-coordinated
crystal structures [91]. An extremely challenging and fascinating question is whether
we can devise inverse optimization techniques to control cancer?
It is clear that theoretical methods based in the physical and mathematical sciences
offer many different fruitful ways to contribute to tumor research. However, for
this approach to be successful, intensive interactions with cell biologists, oncologists,
radiologists, clinicians, physicists, chemists, engineers, and applied mathematicians are
essential. Such an interdisciplinary approach appears to be necessary in order to
control this deadly disease. This could be achieved most effectively if we could have
an analog of the “Manhattan Project” in which there was a single facility with such an
interdisciplinary team of scientists dedicated to this supreme achievement.
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Glossary
• Neoplasm: A neoplasm is a synonym for a tumor.
• Glioma: A collection of tumors arising from the glial cells or their precursors in the
central nervous system.
• Cellular automaton: A spatially and temporally discrete model that consists of a
grid of cells, with each cell being in one of a number of predefined states. The state
of a cell at a given point in time depends on the state of itself and its neighbors at
the previous discrete time point. Transitions between states are determined by a
set of local rules.
• Ising model : The Ising model is an idealized statistical-mechanical model of
ferromagnetism that is based on simple local-interaction rules, but nonetheless lead
to basic insights and features of real magnets, such as phase transitions with a
critical point.
• Voronoi cell : Given a set of points, the Voronoi cell is the cell that is formed about
an arbitrary point in the set by finding the region of space closer to that point than
any other point in the system (Torquato, 2002).
• Delaunay triangulation: Given a Voronoi graph (a set of Voronoi cells), the
Delaunay graph is its dual that results from joining all pairs of sites that share a
Voronoi face. If this graph consists of only simplices, the graph is called a Delaunay
triangulation (Torquato, 2002).
• Quiescent : A cell is considered quiescent if it is in the G0 phase of the cell cycle
and is not actively dividing.
• Necrotic: A cell is considered necrotic if it has died due to injury or disease, such
as abnormally low oxygen levels.
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Figure Legends
Figure 1. A schematic plot of the Ising model for an idealized ferromagnet. The
model consists of spins that can be in one of two states (up or down) arranged in
this case on a square lattice. In its simplest rendition, each spin interacts only with
its nearest neighbors. Such simple local interaction rules can result in rich collective
behavior depending on the temperature of the system.
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Figure 2. A T1-contrast enhanced brain MRI-scan showing a right frontal GBM
tumor, as adapted from Ref. [11]. Perifocal hypointensity is caused by significant
edema formation. The hyper-intense, white region (ring-enhancement) reflects an area
of extensive blood-brain/tumor barrier leakage. Since this regional neovascular setting
provides tumor cells with sufficient nutrition it contains the highly metabolizing, e.g.
dividing, tumor cells Therefore, this area corresponds to the outermost concentric shell
of highly proliferating neoplastic cells in our model (see Figure 5).
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Figure 3. MTS-gel assay showing a central spheroid with multiple “chain”-like
invasion pathways leading towards the boundary (magnification: x 200), as adapted
from Ref. [11].
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Figure 4. Two-dimensional space tiled into Voronoi cells, as adapted from Ref. [11].
Points represent sites and lines denote boundaries between cells. Figures (a) and (b)
depict a very small section of a lattice. (a) shows the Voronoi cells, while (b) shows
both the Voronoi cells, along with the Delaunay tessellation. Figures (c) and (d) show
a more representative section of the lattice, with the variable density of sites evident.
Panel (c) shows the entire lattice section, (d) shows the same section with the darkened
cells representing a tumor.
Toward an Ising Model of Cancer and Beyond 39
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
444444444444444444444
Rt
δp
δn
Figure 5. A cross-section of an idealized solid tumor, as adapted from Ref. [11]. The
inner gray region is composed of necrotic tissue. The cross-hatched layer is composed
of living, quiescent cells (non-proliferative). It has a thickness δn. The outer shell,
with thickness δp, is composed of proliferative cells. Both length scales δn and δp are
determined by nutritional needs of the cells via diffusional transport.
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Figure 6. An illustration of the minimalist proliferation algorithm through a cross-
section of the solid tumor [11]. (a) A tumor contains necrotic (black), non-proliferative
(yellow or light gray) and proliferative cells (red or dark gray). The average overall
tumor radiusRt and the necrotic region radiusRn are shown. (b) Two non-proliferative
cells that more than δn away from the tumor edge are turned into necrotic and two
proliferative cells are selected with probability pd to check for division. If there are non-
tumorous cells within a distance δd from the selected proliferative cell, it will divide;
otherwise, it will turn into a non-proliferative cell. (c) One of the selected proliferative
cell divides and the other turns into a non-proliferative cell.
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Figure 7. The development of the central section of a tumor as a function of time, as
adapted from Ref. [11]. Correspond to: (a) the initial tumor spheroid stage, (b) time
to first detectable lesion, (c) time at diagnosis and (d) time at death. The dark gray
outer region is comprised of proliferating cells, the light gray is non-proliferative cells
and the black is necrotic cells. The length scales are given in millimeters.
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Figure 8. A cut-away view a simulated tumor generated from the minimalist CA
algorithm [11]. The inner necrotic core is not depicted in this view. The yellow (light
gray) region is comprised of nonproliferative cells and the red (dark gray) shell depicts
the proliferative cells.
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Figure 9. Plots of the radius and volume of the tumor versus time, as adapted from
Ref. [11]. The lines correspond to simulation predictions, using the first parameter
set given in the text. The plotted points reflect the test case derived from the medical
literature. A quantitative comparison of the simulation with the test case is given in
Table 2.
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Figure 10. (a) A plot of probability of emergence P versus the degree of mutation
α, i.e., growth advantage (α > 1) or disadvantage (α < 1), as adapted from Ref. [12].
The error bars indicate confidence intervals defined by one standard deviation from
the mean. Each data point represents the average of roughly 100 simulated tumors.
The line is drawn as a guide for the eye. (b) A cut-away view a simulated tumor with
a mutated population. The inner necrotic core is not depicted in this view. The yellow
(light gray) region is comprised of nonproliferative cells and the red (dark gray) shell
depicts the proliferative cells of the primary strain and the blue (darker gray) shows
the proliferative cells of the secondary strain.
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Figure 11. The effects of the emergence of a subpopulation on the tumor geometry,
as adapted from Ref. [12]. The center of mass of the tumor is significantly shifted as
the growth of the subpopulation,
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Figure 12. Volume of a simulated tumor with an emergent subpopulation in time, as
adapted from Ref. [12]. Volumes of tumors composed entirely of the primary strain and
the secondary strain are also shown and labeled “base p0” and “high p0,” respectively.
Each tumor is set to have the same volume at some “diagnosis” time t0. Note that the
emerging tumor’s dynamics initially follow the base case, but later follow the highly
aggressive case.
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Figure 13. Initial images of two-strain tumors, as adapted from Ref. [13]. The
resistant subpolulation is localized (left panel) and scattered (right panel). The blue
cells of each tumor belong to the resistant subpopulation, while the blues ones belong
to the sensitive subpopoluation.
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Figure 14. Survival times associated with continuously mutating tumors, as adapted
from Ref. [13]. This figure depicts data of the mean survival time (with error bars) as
a function of φ, the expected fraction of tumor cells that mutate at each instance of
treatment.
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Figure 15. Images of continuously mutating tumors, as adapted from Ref. [13].
Shown are representative images of tumors with small φ (left panel), intermediate φ
(middle panel) and large φ (right panel). The distinct clonal sub-populations in each
tumor are represented with a different color, ranging from red (highest γ-values) to
violet (lowest γ-values). All tumors here are fully-developed.
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Figure 16. The temporal development of a tumor growing in a two-dimensional
representation of the cranium in space, as adapted from Ref. [21]. (a) After 40 days,
the dimensionless area is 0.0049 units2, with 30% of the cells being proliferative, 66.4%
being hypoxic and 3.6% being necrotic. (b) After 65 days, the dimensionless area is
0.0195 units2, with 51.2% of the cells being proliferative, 33.0% being hypoxic and
15.8% being necrotic. (c) After 85 days, the dimensionless area is 0.0362 units2, with
48.2% of the cells being proliferative, 16.8% being hypoxic and 35.0% being necrotic.
(d) After 115 days, the dimensionless area is 0.0716 units2, with 45.1% of the cells
being proliferative, 18.6% being hypoxic and 36.3% being necrotic. The deep blue
outer region (darkest of the grays in black and white) is comprised of proliferative cells,
the yellow region (lightest of the grays in black and white) consists of hypoxic cells and
the black center contains necrotic cells. Green cells (intermediate gray shade in black
and white) are apoptotic. The white speckled region of space represents locations in
which the tumor cannot grow. The lines represent blood vessels. If viewing the image
in color, red vessels were part of the original tissue vasculature, and the purple vessels
grew via angiogenesis.
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Figure 17. Example of a weighted graph and the resulting minimal spanning tree,
as adapted from Ref. [61]. (a) Shows all of the edges and nodes in a graph, with
the weight of each edge indicated next to the edge. Graph edges are depicted by
broken lines. (b) Shows the minimal spanning tree for this graph, which is the set of
edges that connects every node in the graph in the tree with the lowest total weight.
Edges included in the tree are shown as solid lines, while edges not included remain
broken lines. The total weight of the tree in (b) is 40, and the occupied edge density
(number of edges included in the tree divided by total number of edges in the graph)
is 15/25 = 0.6. (c) Shows the invasion percolation network for the same graph. Note
that the invasion percolation network may have loops and in this case there are two
closed loops. If loop formation is prevented (resulting in the highest weight edge in any
loop remaining unoccupied) the result is the acyclic invasion percolation network. As
can be readily seen by comparing figures (b) and (c) the acyclic invasion percolation
network is identical to the minimal spanning tree.
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Figure 18. Examples of (a) backbone of generalized invasive spanning tree (GIST)
(b) generalized minimal spanning tree (GMST), as adapted from Ref. [61].
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Figure 19. A schematic illustration of heterogeneous materials, as adapted from Ref.
[62]. Left panel: A two-phase heterogeneous material with properties K1 and K2 and
volume fractions φ1 and φ2. The quantity Ki represents any general physical property
of phase i (e.g., diffusion coefficient, electrical or thermal conductivity, elastic moduli,
viscosity, and magnetic permeability). The material phases can either be solid, liquid
or gas depending on the specific context. Here L and ℓ represent the macroscopic and
microscopic length scales, respectively. Right panel: When L is much bigger than ℓ,
the heterogeneous material can be replaced by homogeneous medium with an effective
property Ke.
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Figure 20. Two-phase composite whose interface is the Schwartz P minimal
surface, which simultaneously optimizes heat and electrical conduction [81] or electrical
conduction and elastic moduli [82]. The image at the top shows the two-phase
composite. The bottom left image shows only one of the phases (green), which can be
seen to be the Schwartz P minimal surface, and the bottom right image shows only
the other phase (red).
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Figure 21. The ground-state structures for isotropic pair interaction potentials
obtained via “inverse” optimization techniques discussed in the text. Left panel: A
diamond-crystal ground state [89]. Right panel: A disordered ground state [90].
